Abstract
Abstract
Rationale
Prostate cancer treatment response may be automatically quantified using a molecular imaging analysis platform targeting prostate-specific membrane antigen (PSMA).
Methods
A retrospective analysis of patients with castration-sensitive prostate cancer who underwent PSMA-targeted molecular imaging prior to and 3 months or more after treatment was conducted. Disease burden was analyzed with aPROMISE, an artificial intelligence imaging platform that automatically quantifies PSMA-positive lesions. The calculated PSMA scores for prostate/bed, nodal, and osseous disease sites were compared with prostate-specific antigen (PSA) values.
Results
Of 30 eligible patients, the median decline in prostate/bed, nodal, and osseous disease PSMA scores were 100% (range 52–100%), 100% (range − 87–100%), and 100% (range − 21–100%), respectively. PSMA score decline was significantly associated with PSA decline.
Conclusion
Changes in aPROMISE PSMA scores are associated with changes in PSA and may quantify treatment response.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Molecular Medicine,Biophysics,Computer Science (miscellaneous)
Reference27 articles.
1. Afshar-Oromieh A et al (2018) Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging 45:2045–2054
2. Aggarwal R et al (2018) Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol 1:78–82
3. Anand A et al (2016) Analytic validation of the automated bone scan index as an imaging biomarker to standardize quantitative changes in bone scans of patients with metastatic prostate cancer. J Nucl Med off Publ Soc Nucl Med 57:41–45
4. Anand A et al (2020) Assessing radiographic response to 223Ra with an automated bone scan index in metastatic castration-resistant prostate cancer patients. J Nucl Med off Publ Soc Nucl Med 61:671–675
5. Calais J et al (2022) Prospectively planned and Independent validation of aPROMISE in a phase III CONDOR study for rapid lesion detection and standardized quantitative evaluation for 18F-DCFPyL (PSMA) imaging in prostate cancer. J Nucl Med 63:2496
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献